 Angiotensin-Converting Enzyme Inhibitors
"Angiotensin-Converting Enzyme Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.
| Descriptor ID |
D000806
|
| MeSH Number(s) |
D27.505.519.389.745.085
|
| Concept/Terms |
Angiotensin-Converting Enzyme Inhibitors- Angiotensin-Converting Enzyme Inhibitors
- Angiotensin Converting Enzyme Inhibitors
- Inhibitors, Kininase II
- Kininase II Antagonists
- Kininase II Inhibitors
- Angiotensin I-Converting Enzyme Inhibitors
- Angiotensin I Converting Enzyme Inhibitors
- Antagonists, Angiotensin-Converting Enzyme
- Antagonists, Angiotensin Converting Enzyme
- Antagonists, Kininase II
- Inhibitors, ACE
- ACE Inhibitors
- Inhibitors, Angiotensin-Converting Enzyme
- Enzyme Inhibitors, Angiotensin-Converting
- Inhibitors, Angiotensin Converting Enzyme
- Angiotensin-Converting Enzyme Antagonists
- Angiotensin Converting Enzyme Antagonists
- Enzyme Antagonists, Angiotensin-Converting
|
Below are MeSH descriptors whose meaning is more general than "Angiotensin-Converting Enzyme Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Angiotensin-Converting Enzyme Inhibitors".
This graph shows the total number of publications written about "Angiotensin-Converting Enzyme Inhibitors" by people in this website by year, and whether "Angiotensin-Converting Enzyme Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 | | 1995 | 2 | 3 | 5 | | 1996 | 1 | 0 | 1 | | 1998 | 2 | 1 | 3 | | 1999 | 1 | 2 | 3 | | 2000 | 4 | 0 | 4 | | 2001 | 2 | 2 | 4 | | 2002 | 1 | 3 | 4 | | 2003 | 2 | 5 | 7 | | 2004 | 6 | 4 | 10 | | 2005 | 3 | 3 | 6 | | 2006 | 4 | 3 | 7 | | 2007 | 6 | 3 | 9 | | 2008 | 5 | 2 | 7 | | 2009 | 2 | 2 | 4 | | 2010 | 4 | 5 | 9 | | 2011 | 3 | 5 | 8 | | 2012 | 1 | 5 | 6 | | 2013 | 2 | 1 | 3 | | 2014 | 3 | 2 | 5 | | 2015 | 5 | 2 | 7 | | 2016 | 3 | 5 | 8 | | 2017 | 4 | 2 | 6 | | 2018 | 3 | 5 | 8 | | 2019 | 1 | 1 | 2 | | 2020 | 2 | 1 | 3 | | 2021 | 2 | 6 | 8 | | 2022 | 1 | 3 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Angiotensin-Converting Enzyme Inhibitors" by people in Profiles.
-
Smith SM, Winterstein AG, Gurka MJ, Walsh MG, Keshwani S, Libby AM, Hogan WR, Pepine CJ, Cooper-DeHoff RM. Initial Antihypertensive Regimens in Newly Treated Patients: Real World Evidence From the OneFlorida+ Clinical Research Network. J Am Heart Assoc. 2023 01 03; 12(1):e026652.
-
Valente R, Crippa S, Arnelo U, Vanella G, Zerboni G, Zarantonello L, Fogliati A, Arcidiacono PG, Vujasinovic M, Lohr JM, Falconi M, Capurso G, Del Chiaro M. The use of ace inhibitors influences the risk of progression of BD-IPMNs under follow-up. Pancreatology. 2022 May; 22(4):516-524.
-
Thomas SA, Puskarich M, Pulia MS, Meltzer AC, Camargo CA, Courtney DM, Nordenholz KE, Kline JA, Kabrhel C. Association Between Baseline Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin?Receptor Blockers and Death Among Patients Tested for COVID-19. J Clin Pharmacol. 2022 06; 62(6):777-782.
-
Villa C, Auerbach SR, Bansal N, Birnbaum BF, Conway J, Esteso P, Gambetta K, Hall EK, Kaufman BD, Kirmani S, Lal AK, Martinez HR, Nandi D, O'Connor MJ, Parent JJ, Raucci FJ, Shih R, Shugh S, Soslow JH, Tunuguntla H, Wittlieb-Weber CA, Kinnett K, Cripe L. Current Practices in Treating Cardiomyopathy and Heart Failure in Duchenne Muscular Dystrophy (DMD): Understanding Care Practices in Order to Optimize DMD Heart Failure Through ACTION. Pediatr Cardiol. 2022 Jun; 43(5):977-985.
-
Breathett KK, Xu H, Sweitzer NK, Calhoun E, Matsouaka RA, Yancy CW, Fonarow GC, DeVore AD, Bhatt DL, Peterson PN. Is the affordable care act medicaid expansion associated with receipt of heart failure guideline-directed medical therapy by race and ethnicity? Am Heart J. 2022 02; 244:135-148.
-
Vaduganathan M, Greene SJ, Zhang S, Solomon N, Chiswell K, Devore AD, Butler J, Heidenreich PA, Huang JC, Kittleson MM, Joynt Maddox KE, Mcdermott JJ, Owens AT, Peterson PN, Solomon SD, Vardeny O, Yancy CW, Fonarow GC. Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure. J Card Fail. 2022 04; 28(4):554-563.
-
Kim SH, Brodsky IG, Chatterjee R, Kashyap SR, Knowler WC, Liao E, Nelson J, Pratley R, Rasouli N, Vickery EM, Sarnak M, Pittas AG. Effect of Vitamin D Supplementation on Kidney Function in Adults with Prediabetes: A Secondary Analysis of a Randomized Trial. Clin J Am Soc Nephrol. 2021 08; 16(8):1201-1209.
-
Stokes WA, Molina E, McDermott JD, Morgan RL, Bickett T, Fakhoury KR, Amini A, Karam SD. Survival impact of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in head and neck cancer. Head Neck. 2021 11; 43(11):3255-3275.
-
White BM, Anderson SL, Marrs JC. Antihypertensive prescribing patterns and hypertension control in females of childbearing age. Am J Health Syst Pharm. 2021 07 09; 78(14):1317-1322.
-
Flaten HK, Sonn BJ, Saben JL, Shelton SK, Schwartz J, Ryall K, Monte AA. Genomic markers associated with successful treatment of hypertension with lisinopril: A?pilot?study. Int J Clin Pharmacol Ther. 2021 Jul; 59(7):506-510.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|